Jose Alemparte, MD
Cardiology · Fort Smith, ARNPI 1679574255
Payments from drug & device makers
Across 474 payments — averaging $25.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Medtronic$2K
- Novartis$2K
- Amgen$933
- Johnson & Johnson$875
- Boehringer Ingelheim$863
- plus $4K from 24 others
What the payments were for
- Food & beverage$11,79498%
- Education$2032%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 55 | $1,974 |
| Medtronic(2 entities) | 23 | $1,806 |
| Novartis | 93 | $1,577 |
| Amgen | 45 | $933 |
| Johnson & Johnson | 45 | $875 |
| Boehringer Ingelheim | 35 | $863 |
| Merck | 40 | $656 |
| Sanofi-aventis U.S. LLC | 27 | $554 |
| Abiomed | 6 | $535 |
| Pfizer | 20 | $445 |
| Bayer | 17 | $395 |
| AstraZeneca | 26 | $375 |
| Astellas Pharma US Inc | 5 | $264 |
| E.r. Squibb & Sons, L.L.C. | 8 | $224 |
| Shockwave Medical, Inc | 1 | $112 |
| Esperion Therapeutics, Inc. | 6 | $75 |
| Novo Nordisk | 3 | $53 |
| Lilly USA, LLC | 3 | $45 |
| Philips North America LLC | 2 | $43 |
| Lexicon Pharmaceuticals, Inc. | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Gilead | 2 | $23 |
| Eisai Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
| Zyla Life Sciences, Inc. | 1 | $12 |
| Cashflow Solutions, LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$655
- Impella$498
- JARDIANCE$360
- Cobalt$276
- COBALT DR MRI SURESCAN$264
- XARELTO$249
- Repatha$248
- AZURE XT DR MRI SURESCAN$129
- Kerendia$125
- ELIQUIS$125
- PRALUENT$125
- Claria MRI$125
- LUX-Dx Insertable Cardiac Monitor$124
- EMBLEM MRI S-ICD$122
- CAMZYOS$121
- VIGILANT$121
- Farapulse$119
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$112
- GENERAL - THERAPIES$109
- EMBLEM$102
How this compares
Too few cardiology providers in Arkansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 317 | $236,566 |
| EntrestoSacubitril/Valsartan | 165 | $149,103 |
| XareltoRivaroxaban | 102 | $81,556 |
| MultaqDronedarone Hcl | 29 | $40,732 |
| JardianceEmpagliflozin | 24 | $14,241 |
| BrilintaTicagrelor | 18 | $14,150 |
| Ranolazine ErRanolazine | 199 | $11,445 |
| Amiodarone Hcl | 337 | $3,662 |
| Clonidine | 28 | $3,618 |
| Metoprolol Succinate | 424 | $3,103 |
| Potassium Chloride | 151 | $2,267 |
| Nebivolol Hcl | 59 | $1,927 |
| Carvedilol | 336 | $1,854 |
| ClopidogrelClopidogrel Bisulfate | 257 | $1,597 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 242 | $1,357 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $445 | $236,566317 claims |
| NovartisEntresto | $1,577 | $149,103165 claims |
| Johnson & JohnsonXarelto | $875 | $81,556102 claims |
| Sanofi-aventis U.S. LLCMultaq | $554 | $40,73229 claims |
| Boehringer IngelheimJardiance | $863 | $14,24124 claims |
| AstraZenecaBrilinta | $375 | $14,15018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Arkansason file to place this against a meaningful peer group, so we don't.
Other cardiology in Fort Smith
- Ronald KantolaFort Smith$16K
- Ayman AlshamiPine Bluff$14K
- Benjamin FolkLake Village$3K
- Otis WarrMountain Home$2K
- Margaret KuykendallBatesville$899
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.